Novo Nordisk A/S’s Revenue Growth at a glance
Novo Nordisk A/S reports revenue growth of 25% for Dec 2024. The prior period recorded 31.3% (Dec 2023). Year over year the metric moved −6.2 pts (−19.9%). The rolling three-period average stands at 27.3%. Data last refreshed Dec 7, 2025, 2:50 AM.
Latest reading
25% · Dec 2024
YoY movement
−6.2 pts (−19.9%)
Rolling average
27.3%
Current Revenue Growth
25%
−6.2 pts
−19.9%
Rolling average
27.3%
Latest Value
25%
Dec 2024
YoY Change
−6.2 pts
Absolute
YoY Change %
−19.9%
Rate of change
3-Period Avg
27.3%
Smoothed
Narrative signal
Novo Nordisk A/S’s revenue growth stands at 25% for Dec 2024. Year-over-year, the metric shifted by −6.2 pts, translating into a −19.9% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How revenue growth shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports revenue growth of 25%. Evaluate revenue acceleration, seasonality, and long-term expansion for U.S. equities using annual growth data.
How to read revenue growth
Consistent double-digit revenue growth typically indicates demand strength and market share gains. Sharp decelerations may point to competitive or macro headwinds.
Balancing growth with profitability
Growth only creates value when paired with improving margins or cash generation. Pair revenue growth with profitability metrics to judge overall health.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
84.7%
Operating Margin
44.2%
Net Profit Margin
34.8%
Return on Equity
70.4%
Return on Assets
21.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s revenue growth profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current revenue growth?
As of Dec 2024, Novo Nordisk A/S reports revenue growth of 25%. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's revenue growth trending year over year?
Year-over-year, the figure shifts by −6.2 pts (−19.9%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does revenue growth matter for Novo Nordisk A/S?
Revenue growth measures the percentage change in top-line sales compared with the prior period. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's revenue growth above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 27.3%. Comparing the latest reading of 25% to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's revenue growth refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:50 AM and updates automatically every 24 hours, keeping your valuation inputs current.